Abera Bioscience P/B

Mitä Abera Bioscience tekee? Abera Bioscience AB develops pharmaceutical products through research and development, focusing on vaccine candidates using its delivery platform. The company aims to advance these candidates to late pre-clinical or early clinical stages before seeking licensing partners for further development. Its technology targets pneumococci and immunooncology, with operations centered in the Nordic market. The business model relies on securing partnerships for vaccine development rather than direct sales, leveraging its platform to attract collaborators in the medical and microbiological sectors. The company's revenue stream comes from licensing agreements with partners who take over further development and commercialization of the vaccine candidates. Abera Bioscience does not sell products directly but instead generates income through these partnerships, which align with its focus on late pre-clinical and early clinical phases. The Nordic market serves as the primary operational region, where the company collaborates with entities in the medical, molecular, and microbiological fields to advance vaccine research. Abera Bioscience AB's business strategy emphasizes platform-based vaccine development, targeting pneumococci and immunooncology areas. The company seeks to transition its vaccine candidates to partners who can handle later-stage development, ensuring the platform's value is realized through collaborative agreements. This approach allows Abera to focus on R&D while partners manage clinical trials and market entry, creating a sustainable revenue model without direct product sales. Abera Bioscience on yksi Eurpooliin suosituimmista yhtiöistä.